IL234537A - Pyrazole derivative for the treatment of acute inflammatory disease of chronic obstructive pulmonary disease - Google Patents

Pyrazole derivative for the treatment of acute inflammatory disease of chronic obstructive pulmonary disease

Info

Publication number
IL234537A
IL234537A IL234537A IL23453714A IL234537A IL 234537 A IL234537 A IL 234537A IL 234537 A IL234537 A IL 234537A IL 23453714 A IL23453714 A IL 23453714A IL 234537 A IL234537 A IL 234537A
Authority
IL
Israel
Prior art keywords
treatment
disease
obstructive pulmonary
pulmonary disease
chronic obstructive
Prior art date
Application number
IL234537A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL234537A publication Critical patent/IL234537A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL234537A 2012-03-20 2014-09-08 Pyrazole derivative for the treatment of acute inflammatory disease of chronic obstructive pulmonary disease IL234537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
IL234537A true IL234537A (en) 2016-09-29

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234537A IL234537A (en) 2012-03-20 2014-09-08 Pyrazole derivative for the treatment of acute inflammatory disease of chronic obstructive pulmonary disease

Country Status (29)

Country Link
US (2) US9339491B2 (enExample)
EP (1) EP2827860B1 (enExample)
JP (1) JP6091593B2 (enExample)
KR (1) KR101793777B1 (enExample)
CN (1) CN104203234B (enExample)
AU (1) AU2013237503B2 (enExample)
BR (1) BR112014023107B1 (enExample)
CA (1) CA2866108C (enExample)
CL (1) CL2014002471A1 (enExample)
CY (1) CY1118327T1 (enExample)
DK (1) DK2827860T3 (enExample)
ES (1) ES2605942T3 (enExample)
HR (1) HRP20161514T1 (enExample)
HU (1) HUE032004T2 (enExample)
IL (1) IL234537A (enExample)
LT (1) LT2827860T (enExample)
MA (1) MA37455B1 (enExample)
MX (1) MX351996B (enExample)
NZ (1) NZ628392A (enExample)
PH (1) PH12014502107B1 (enExample)
PL (1) PL2827860T3 (enExample)
PT (1) PT2827860T (enExample)
RU (1) RU2625762C2 (enExample)
SG (1) SG11201404941WA (enExample)
SI (1) SI2827860T1 (enExample)
TN (1) TN2014000350A1 (enExample)
TW (1) TWI583381B (enExample)
WO (1) WO2013139809A1 (enExample)
ZA (1) ZA201405871B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR20180119597A (ko) * 2016-03-08 2018-11-02 메레오 바이오파마 1 리미티드 염증 상태의 급성 악화의 치료를 위한 투약법
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114748622B (zh) 2017-10-05 2024-09-24 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
KR102899004B1 (ko) 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
AU2018381874B2 (en) 2017-12-11 2024-08-15 Mereo Biopharma 1 Limited Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
CN114141383A (zh) * 2021-12-17 2022-03-04 湖南大学 慢阻肺智能护理方法、装置及系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009973A1 (en) * 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1200352A1 (en) 2015-08-07
AU2013237503A1 (en) 2014-09-25
LT2827860T (lt) 2016-12-12
EP2827860A1 (en) 2015-01-28
CA2866108A1 (en) 2013-09-26
RU2625762C2 (ru) 2017-07-18
AU2013237503B2 (en) 2016-05-26
RU2014141893A (ru) 2016-05-10
US20150031736A1 (en) 2015-01-29
JP2015510916A (ja) 2015-04-13
US20160243081A1 (en) 2016-08-25
BR112014023107A2 (enExample) 2017-06-20
US9339491B2 (en) 2016-05-17
PH12014502107A1 (en) 2014-12-10
WO2013139809A1 (en) 2013-09-26
KR101793777B1 (ko) 2017-11-03
JP6091593B2 (ja) 2017-03-08
PH12014502107B1 (en) 2019-11-27
HUE032004T2 (en) 2017-08-28
EP2827860B1 (en) 2016-10-26
MA37455A1 (fr) 2016-08-31
CN104203234A (zh) 2014-12-10
NZ628392A (en) 2016-06-24
CL2014002471A1 (es) 2015-01-09
MX2014011291A (es) 2014-10-13
CY1118327T1 (el) 2017-06-28
KR20140146073A (ko) 2014-12-24
SG11201404941WA (en) 2014-10-30
CN104203234B (zh) 2017-06-13
PL2827860T3 (pl) 2017-09-29
PT2827860T (pt) 2016-12-20
CA2866108C (en) 2017-03-07
HRP20161514T1 (hr) 2016-12-30
TWI583381B (zh) 2017-05-21
TN2014000350A1 (en) 2015-12-21
ES2605942T3 (es) 2017-03-17
DK2827860T3 (en) 2016-12-12
SI2827860T1 (sl) 2017-01-31
ZA201405871B (en) 2016-01-27
MX351996B (es) 2017-11-06
BR112014023107B1 (pt) 2021-08-10
TW201343162A (zh) 2013-11-01
MA37455B1 (fr) 2017-03-31

Similar Documents

Publication Publication Date Title
IL234537A (en) Pyrazole derivative for the treatment of acute inflammatory disease of chronic obstructive pulmonary disease
SG188298A1 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20150046110A (ko) 피르페니돈 치료제의 투여 방법
US20170042890A1 (en) Methods of reducing decline in vital capacity
JP2020521726A (ja) Pde9阻害剤を含む医薬組成物
Joos et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients
IL298833A (en) Methods for treating or preventing chronic kidney disease
JP6830895B2 (ja) ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン
CN110167559A (zh) 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法
JP6080324B2 (ja) キサンチン誘導体
HK1200352B (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
Iribarnegaray et al. Antithymocyte globulin treatment for chronic lung allograft dysfunction in lung transplant recipients: experience from a national reference transplant center
Tripp et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects
JP2021533158A (ja) 治療の実施方法
WO2023056463A1 (en) Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome
JP2025530668A (ja) Ripk1阻害剤としてのイソオキサゾリジン及びその使用
CN1985833A (zh) 雌酚酮衍生物ea204在制备血管平滑肌松弛剂中的用途
Symonides et al. Intravenous dexamethasone administered perioperatively does not cause hyperglycaemia-initial report: A-536
Fessenmeyer et al. Prognosis value of ECG abnormalities, myocardial specific enzymes and cardiac function in spontaneous subarachnoid hemorrhage: A-533

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed